SCHEMBL3501015

SCHEMBL3501015

Cc1ccc(-c2cc(NCCNc3cc(-c4cccs4)[nH]n3)n[nH]2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 1.00
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
NFKB1 P19838 3/20 0.48
NFKB2 Q00653 3/20 0.48
RELA Q04206 3/20 0.48
MAPT P10636 2/20 0.48
AHR P35869 1/20 0.48
FLT3 P36888 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPY5R Q15761 1/20 0.41
TNIK Q9UKE5 1/20 0.41
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3500464 0.99 APP (0.98) APPKMT2AMEN1NFKB1NFKB2
SCHEMBL13312221 0.88 APP (0.78) APPKMT2AMEN1NFKB1NFKB2
SCHEMBL13312316 0.88 APP (0.78) APPKMT2AMEN1MAPTAHR
Hydrochloric Acid SCHEMBL3497967 0.86 APP (0.76) APPKMT2AMEN1MAPTAHR
SCHEMBL13312204 0.85 APP (0.72) APPKMT2AMEN1MAPTAHR
SCHEMBL3500395 0.84 APP (0.72) APPKMT2AMEN1NFKB1NFKB2
SCHEMBL3501043 0.84 APP (0.72) APPKMT2AMEN1NFKB1NFKB2
SCHEMBL13312311 0.79 APP (0.64) APPKMT2AMAPTAHRSMN1; SMN2
Hydrochloric Acid SCHEMBL3501348 0.78 APP (0.63) APPKMT2AMAPTAHRSMN1; SMN2
SCHEMBL3502921 0.77 APP (0.63) APPKMT2AMEN1MAPTFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 US disclosed
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 US disclosed
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS APP, BACE1, APBA1 APP 1/4885KMT2A 4668/4885MEN1 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.